Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12574544 | 0.85 | MAP3K14 (0.35) | MAP3K14 | |
| SCHEMBL2026135 | 0.85 | MAP3K14 (0.35) | MAP3K14 | |
| SCHEMBL2018943 | 0.77 | CRHR1 (0.34) | — | |
| SCHEMBL2018098 | 0.75 | MAP3K14 (0.34) | MAP3K14 | |
| SCHEMBL2018099 | 0.74 | HTR2A (0.36) | MAP3K14 | |
| SCHEMBL2022299 | 0.69 | ALDH1A1 (0.40) | — | |
| SCHEMBL12574543 | 0.69 | ALDH1A1 (0.40) | — | |
| SCHEMBL12750353 | 0.67 | CRHR1 (0.33) | MAP3K14 | |
| SCHEMBL803154 | 0.67 | ITGB2 (0.41) | MAP3K14 | |
| SCHEMBL12124884 | 0.65 | SLC6A2 (0.39) | MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338591-B2 | 3-aryl-5,6-disubstituted pyridazines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-12-25 | — | — | US | disclosed |
| US-8338591-B2 | 3-aryl-5,6-disubstituted pyridazines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-12-25 | — | — | US | disclosed |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORPORATION (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORPORATION (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORPORATION (US) | 2011-06-30 | — | — | US | disclosed |
| EP-1745039-A4 | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES | NEUROGEN CORP (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1745039-A2 | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES | Neurogen Corporation (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006004589-A2 | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES | NEUROGEN CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | MMP25, MMP9, MMP3 | MAP3K14 1310/4885C5AR1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.